Drugs / HS-10381
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05378178 | Jun 2022 → Dec 2023 | neoplasm | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10381 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05378178 ↗ |
| Action | Inhibit | “SHP2 inhibitor” NCT05378178 ↗ |
| Modality | Small molecule | “HS-10381 is a small molecular, oral potent, SHP2 inhibitor.” NCT05378178 ↗ |
| Route | Oral | “HS-10381 given orally QD” NCT05378178 ↗ |